Sarissa Capital Management LP Buys Alexion Pharmaceuticals Inc, AbbVie Inc, Jazz Pharmaceuticals PLC, Sells Mersana Therapeutics Inc

Aug 18, 2020

Greenwich, CT, based Investment company Sarissa Capital Management LP (Current Portfolio) buys Alexion Pharmaceuticals Inc, AbbVie Inc, Jazz Pharmaceuticals PLC, BioCryst Pharmaceuticals Inc, sells Mersana Therapeutics Inc during the 3-months ended 2020Q2, according to the most recent filings of the investment company, Sarissa Capital Management LP. As of 2020Q2, Sarissa Capital Management LP owns 12 stocks with a total value of $899 million. These are the details of the buys and sells.

New Purchases: BCRX,
Added Positions: ALXN, ABBV, JAZZ, ALKS, IRWD, INVA, ICPT,
Reduced Positions: MRSN,

For the details of Sarissa Capital Management LP's stock buys and sells, go to https://www.gurufocus.com/guru/sarissa+capital+management+lp/current-portfolio/portfolio

These are the top 5 holdings of Sarissa Capital Management LP

Biogen Inc (BIIB) - 643,000 shares, 19.14% of the total portfolio.
Alkermes PLC (ALKS) - 7,825,000 shares, 16.89% of the total portfolio. Shares added by 8.79%
Ironwood Pharmaceuticals Inc (IRWD) - 14,040,000 shares, 16.12% of the total portfolio. Shares added by 3.81%
Jazz Pharmaceuticals PLC (JAZZ) - 928,100 shares, 11.39% of the total portfolio. Shares added by 21.32%
Innoviva Inc (INVA) - 6,414,000 shares, 9.97% of the total portfolio. Shares added by 2.76%

New Purchase: BioCryst Pharmaceuticals Inc (BCRX)

Sarissa Capital Management LP initiated holding in BioCryst Pharmaceuticals Inc. The purchase prices were between $1.9 and $5.61, with an estimated average price of $3.96. The stock is now traded at around $4.58. The impact to a portfolio due to this purchase was 0.57%. The holding were 1,075,000 shares as of .

Added: Alexion Pharmaceuticals Inc (ALXN)

Sarissa Capital Management LP added to a holding in Alexion Pharmaceuticals Inc by 450.74%. The purchase prices were between $89.77 and $119.9, with an estimated average price of $105.7. The stock is now traded at around $103.73. The impact to a portfolio due to this purchase was 7.59%. The holding were 743,500 shares as of .

Added: AbbVie Inc (ABBV)

Sarissa Capital Management LP added to a holding in AbbVie Inc by 30915.00%. The purchase prices were between $73.37 and $98.18, with an estimated average price of $87.8. The stock is now traded at around $95.99. The impact to a portfolio due to this purchase was 3.38%. The holding were 310,150 shares as of .

Added: Jazz Pharmaceuticals PLC (JAZZ)

Sarissa Capital Management LP added to a holding in Jazz Pharmaceuticals PLC by 21.32%. The purchase prices were between $95.68 and $121.88, with an estimated average price of $110.39. The stock is now traded at around $122.78. The impact to a portfolio due to this purchase was 2%. The holding were 928,100 shares as of .

Here is the complete portfolio of Sarissa Capital Management LP. Also check out:

1. Sarissa Capital Management LP's Undervalued Stocks
2. Sarissa Capital Management LP's Top Growth Companies, and
3. Sarissa Capital Management LP's High Yield stocks
4. Stocks that Sarissa Capital Management LP keeps buying

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Data is updated daily.